Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient

International Journal of Clinical Oncology

Volumn 14, Issue 5, 2009, Pages 465-467

  Hasegawa, Yasuhisa ^a   Mita, Koji ^a   Matsubara, Akio ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Renal cell carcinoma; Renal transplantation; Sorafenib; Zoledronic acid

Indexed keywords

ALPHA INTERFERON; SORAFENIB; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLEAR CELL CARCINOMA; DRUG EFFICACY; GRAFT DYSFUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; MALE; NEPHRECTOMY; PRIORITY JOURNAL; RECIPIENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; INCIDENTAL FINDINGS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PYRIDINES; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70350507511     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0868-x     Document Type: Article

References (18)

1. S.M. Moudouni A. Lakmichi M. Tligui, et al. 2006 Renal cell carcinoma of native kidney in renal transplant recipients BJU Int 98 298 302 10.1111/j.1464-410X.2006.06267.x 16879668
2. R. Schmidt D. Stippel F. Krings, et al. 1995 Malignancies of genito-urinary system following renal transplantation Br J Urol 75 572 577 10.1111/j.1464-410X.1995.tb07409.x 1:STN:280:DyaK2MzjvVGisA%3D%3D 7613790
3. Y. Neuzillet F. Lay A. Luccioni, et al. 2005 De novo renal cell carcinoma of native kidney in renal transplant recipients Cancer 103 251 257 10.1002/cncr.20745 15593084 (Pubitemid 40129283)
4. J.D. Doublet M.N. Peraldi B. Gattegno, et al. 1997 Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients J Urol 158 42 44 10.1097/00005392-199707000-00012 1:STN:280:DyaK2szivFylsg%3D%3D 9186319 (Pubitemid 27251590)
5. L.E. Ianhez M. Lucon W.C. Nahas, et al. 2007 Renal cell carcinoma in renal transplant patients Urology 69 462 464 10.1016/j.urology.2006.11.007 17382145 (Pubitemid 46428387)
6. T. Nakamoto M. Igawa S. Mitani, et al. 1994 Metastatic renal cell carcinoma arising in a native kidney of a renal transplant recipient J Urol 152 943 945 1:STN:280:DyaK2czivVertg%3D%3D 8051761
7. S. Tang I.K. Cheng V.K. Leung, et al. 2003 Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin J Hepatol 39 875 878 10.1016/S0168-8278(03)00358-1 1:CAS:528:DC%2BD3sXotVertL8%3D 14568274 (Pubitemid 37372201)
8. M. Haas Z. Leko-Mohr P. Roschger, et al. 2003 Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation Kidney Int 63 1130 1136 10.1046/j.1523-1755.2003.00816.x 1:CAS:528:DC%2BD3sXivV2jtrc%3D 12631097 (Pubitemid 36315593)
9. M. Wiesel S. Carl I. Drehmer, et al. 1997 The clinical significance of renal cell carcinoma in dialysis dependent patients in comparison with kidney transplant recipients Urologe A 36 126 129 10.1007/s001200050077 1:STN:280:DyaK2s3ntlGnug%3D%3D 9199039 (Pubitemid 27181622)
10. B. Ljungberg D.C. Hanbury M.A. Kuczyk, et al. 2007 Renal cell carcinoma guideline Eur Urol 51 1502 1510 10.1016/j.eururo.2007.03.035 17408850 (Pubitemid 46634775)
11. T. Hanafusa Y. Ichikawa H. Kishikawa, et al. 1998 Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years Transplantation 66 471 476 10.1097/00007890-199808270-00010 1:STN:280:DyaK1cvgtlGmuw%3D%3D 9734490 (Pubitemid 28415373)
12. P. Deschavanne B. Fertil 1996 A review of human cell radiosensitivity in vitro Int J Radiat Oncol Biol Phys 34 251 266 1:STN:280:DC%2BD38zntlGmug%3D%3D 12118559
13. S. Fossa I. Kjolseth G. Lund 1982 Radiotherapy of metastases from renal cancer Eur Urol 8 340 342 1:STN:280:DyaL3s%2FltlCnsw%3D%3D 6183119 (Pubitemid 13253332)
14. L.S. Rosen D. Gordon S. Tchekmedyian, et al. 2003 Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 3150 3157 10.1200/JCO.2003.04.105 1:CAS:528:DC%2BD2cXpsVWqtb0%3D 12915606 (Pubitemid 46606297)
15. A. Lipton M. Zheng J. Seaman 2003 Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 962 969 10.1002/cncr.11571 1:CAS:528:DC%2BD3sXns1Sjs74%3D 12942563 (Pubitemid 37022096)
16. S.M. Wilhelm C. Carter L. Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D 15466206 (Pubitemid 39331023)
17. B. Escudier T. Eisen W.M. Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530 (Pubitemid 46089673)
18. D. Strumberg J.W. Clark A. Awada, et al. 2007 Safety, pharmacokinetics and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 10.1634/theoncologist.12-4-426 1:CAS:528:DC%2BD2sXmtlSitrs%3D 17470685 (Pubitemid 46698720)